-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
-
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing for HSK21542, a Category 1 drug, in postoperative analgesia for abdominal surgery has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of HSK21542,…
-
NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices
•
The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and Use of Clinically Urgently Needed Medical Devices in Medical Institutions.” These guidelines are designed to address the special clinical needs of patients by allowing the temporary import and use of medical devices that have been…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
•
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III trial for Alecensa (alectinib) in patients with early-stage resected ALK-positive non-small cell lung cancer (NSCLC). The trial demonstrated that the ALK inhibitor significantly improved disease-free survival (DFS) by an unprecedented 76% compared to chemotherapy, meeting…
-
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
•
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink Bioscience, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). This strategic move is set to enhance Eli Lilly’s capabilities in developing innovative oncology treatments through Mablink’s advanced ADC technology. Mablink’s Proprietary ADC TechnologyMablink Bioscience’s…
-
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s Takeda Pharmaceutical Company (TYO: 4502), granting Takeda commercialization rights for its investigational product, BBM-H901. This agreement encompasses the territories of mainland China, Hong Kong, and Macau. Financial details of the partnership have not been disclosed.…
-
MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia
•
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical study in Australia to evaluate the safety, tolerability, and pharmacokinetics of its in-house developed antibiotic, MRX-5. The study will also explore the effects of food on the drug’s pharmacokinetics and is expected to conclude in…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
